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RESEARCH ARTICLE Open Access
Disulfide high mobility group box-1 causes
bladder pain through bladder Toll-like
receptor 4
Fei Ma1,2, Dimitrios E. Kouzoukas1,3,6, Katherine L. Meyer-Siegler4, Karin N. Westlund1,2, David E. Hunt1
and Pedro L. Vera1,2,5*
Abstract
Background: Bladder pain is a prominent symptom in several urological conditions (e.g. infection, painful bladder
syndrome/interstitial cystitis, cancer). Understanding the mechanism of bladder pain is important, particularly when
the pain is not accompanied by bladder pathology. Stimulation of protease activated receptor 4 (PAR4) in the
urothelium results in bladder pain through release of urothelial high mobility group box-1 (HMGB1). HGMB1 has
two functionally active redox states (disulfide and all-thiol) and it is not known which form elicits bladder pain.
Therefore, we investigated whether intravesical administration of specific HMGB1 redox forms caused abdominal
mechanical hypersensitivity, micturition changes, and bladder inflammation in female C57BL/6 mice 24 hours post-
administration. Moreover, we determined which of the specific HMGB1 receptors, Toll-like receptor 4 (TLR4) or
receptor for advanced glycation end products (RAGE), mediate HMGB1-induced changes.
Results: Disulfide HMGB1 elicited abdominal mechanical hypersensitivity 24 hours after intravesical (5, 10, 20 μg/
150 μl) instillation. In contrast, all-thiol HMGB1 did not produce abdominal mechanical hypersensitivity in any of the
doses tested (1, 2, 5, 10, 20 μg/150 μl). Both HMGB1 redox forms caused micturition changes only at the highest
dose tested (20 μg/150 μl) while eliciting mild bladder edema and reactive changes at all doses. We subsequently
tested whether the effects of intravesical disulfide HMGB1 (10 μg/150 μl; a dose that did not produce inflammation)
were prevented by systemic (i.p.) or local (intravesical) administration of either a TLR4 antagonist (TAK-242) or a RAGE
antagonist (FPS-ZM1). Systemic administration of either TAK-242 (3 mg/kg) or FPS-ZM1 (10 mg/kg) prevented HMGB1
induced abdominal mechanical hypersensitivity while only intravesical TLR4 antagonist pretreatment (1.5 mg/ml; not
RAGE) had this effect.
Conclusions: The disulfide form of HMGB1 mediates bladder pain directly (not secondary to inflammation or injury)
through activation of TLR4 receptors in the bladder. Thus, TLR4 receptors are a specific local target for bladder pain.
Keywords: HMGB1, TLR4, RAGE, bladder pain, abdominal mechanical hypersensitivity, urothelium
Background
Common causes of bladder pain are bacterial infection,
painful bladder syndrome/interstitial cystitis (PBS/IC)
and cancer. Bladder pain in the absence of infection or
bladder pathology is a feature of PBS/IC patients, along
with increased frequency and urgency [1]. However,
common rodent models of bladder pain usually produce
significant bladder injury and inflammation [2, 3].
Cyclophosphamide (CYP)-induced cystitis (a widely
used chemical model) elicits severe bladder inflammation
and urothelial damage along with significantly decreased
abdominal mechanical threshold [4, 5]. Interestingly,
CYP-induced bladder pain (abdominal mechanical hyper-
sensitivity) was blocked by systemic administration of a
high-mobility group box 1 protein (HMGB1) neutralizing
antibody or a HMGB1 receptor antagonist without chan-
ging CYP-induced inflammation [5].
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HMGB1 is a ubiquitous and abundant non-histone nu-
clear chromatin-binding protein and a damage-
associated molecular pattern molecule. HMGB1 is
actively secreted in response to inflammatory signals,
acting as a pro-inflammatory molecule in addition to its
passive release from necrotic cells in various organs [6].
The extracellular activities of HMGB1 depend on the
redox state of HMGB1 resulting in activation of different
HMGB1 receptors. Physical/chemical trauma to tissues
or organs results in the release of all-thiol (all-reduced)
HMGB1, which binds to receptor for advanced glycation
end products (RAGE) and potentiates chemotaxis [7].
During inflammation, all-thiol HGMB1 may be oxidized
to the disulfide form of HGMB1, which then binds to
Toll-like receptor 4 (TLR4) to induce cytokine produc-
tion [7]. It is likely that both redox forms contribute to
inflammation resulting from tissue damage. HMGB1 is a
key player in the extracellular environment as a pro-
inflammatory molecule and is also gaining prominence
as a mediator in pain processing [6, 8].
We recently reported that activation of urothelial pro-
tease activated receptor 4 (PAR4) elicits bladder pain in
mice without causing overt bladder inflammation [9]. In
this model, PAR4 activation results in release of urothe-
lial macrophage migration inhibitory factor (MIF) [9]
and HMGB1 [10] along with abdominal mechanical
hypersensitivity, representative of bladder pain. Systemic
pretreatment with MIF antagonist prevented urothelial
HMGB1 release [9] and abdominal mechanical hyper-
sensitivity caused by intravesical PAR4-activating peptide
(PAR4-AP) [9]. Moreover, systemic administration of a
HMGB1 inhibitor also blocked abdominal mechanical
hypersensitivity caused by intravesical PAR4-AP [10].
This indicates that HMGB1 signaling is involved in
PAR4-induced bladder pain. However, it is still not
known which redox form of HMGB1 is responsible for
bladder pain and the type or location of the HMGB1 re-
ceptor mediating the effect. The current study utilized
two redox forms of HMGB1 and receptor-specific antag-
onists in a rodent model of bladder pain without inflam-
mation to explore the etiology of bladder pain.
Methods
Animals
All animal experiments were approved by the Lexington
Veterans Affairs Medical Center Institutional Animal
Care and Use Committee (VER-11-016-HAF) and per-
formed according to the guidelines of the National Insti-
tutes of Health.
Disulfide or all-thiol HMGB1 treatment by intravesical
instillation
13 – 17 week-old female C57BL/6 (SPF, 20-25 g, Jackson
Laboratory, Bar Harbor, ME) were accommodated in
ventilated animal housing with 14/10 light/dark cycle.
Isoflurane-anesthetized mice were transurethrally cathe-
terized (PE10, 11 mm length) and drained of urine.
Disulfide HMGB1, all-thiol HMGB1 (1, 2, 5, 10 and
20 μg; 150 μl, HMGBiotech S.r.l., Milano, Italy) or ve-
hicle control groups (PBS; 150 μl) (3-6/group) were ran-
domly instilled into the bladder lumen and held for
1 hour [9, 10]. In other experiments mouse groups were
pretreated with TLR4 antagonist TAK-242 (30 min prior)
[11], or RAGE antagonist FPS-ZM1 (15 min prior) [12],
either intraperitoneally (TAK-242, 3 mg/kg; FPS-ZM1,
10 mg/kg) or intravesically (TAK-242, 1.5 mg/ml; FPS-
ZM1, 5 mg/ml). Then 10 μg disulfide HMGB1 was in-
stilled and held for 1 hour as described.
Abdominal mechanical hypersensitivity test
Abdominal mechanical hypersensitivity was tested in in-
stilled mice as previously described [10]. Briefly, von
Frey filaments of ascending bending force (0.008, 0.020
0.040, 0.070 g) were pressed to the lower abdominal re-
gion in trials of 10 before (baseline) and 24 hours after
HMGB1 instillation. Positive response was defined as
any one of three behaviors: 1) licking the abdomen, 2)
flinching/jumping, or 3) abdomen withdrawal. Mice
responding more than 30% to the weakest filament
(0.008 g) during baseline testing were excluded from the
study.
Awake mice were tested for abdominal mechanical
hypersensitivity and micturition changes 24 hours after
bladder instillation.
Voided Stain on Paper (VSOP): micturition volume and
frequency
Micturition volume and frequency were measured in
mice using VSOP method [13]. Briefly, mice were
gavaged with water (50 μl/g body weight) to induce diur-
esis, then placed in a plastic enclosure and allowed to
move freely. Filter paper was placed under each mouse
to collect urine during a 2-hour observation period. Mic-
turition volumes were determined by linear regression
using a set of known volumes. Micturition frequency
was defined as the number of micturition within
2 hours.
Histology
Bladders were removed under anesthesia, fixed in 10%
formalin, embedded in paraffin for histology and mice
were euthanized at the end of the experiment.
Paraffin sections (5 μm) were processed for routine
hematoxylin and eosin (H&E) staining. H&E stained sec-
tions were evaluated by a pathologist blinded to the ex-
perimental treatment and scored separately for edema
and inflammation according to the following scale: 0 =
no edema; no infiltrating cells; 1 =mild submucosal
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edema; occasional inflammatory cells; 2 = moderate
edema; several inflammatory cells; 3 = frank edema, vas-
cular congestion; many inflammatory cells [10].
Statistical analyses
Changes in positive response frequency (%) to von Frey
stimulation at baseline and 24 hours after treatment
were evaluated using a within subject 2-way (Time x
Filament Strength) ANOVA. When the Time factor (pre
vs. post) was significant, differences at each filament
strength were compared (pre vs. post) using t-tests with
a multiple comparison adjustment (Holm-Sidak) [14].
Single t-tests (mean = 0) were performed for the histo-
logical scores.
All data are presented as mean ± SE [14], with statis-
tical differences of p ≤ 0.05 considered significant. All
statistical analyses were performed using R [15].
Results
HMGB1 redox form elicits abdominal mechanical
hypersensitivity
We measured responses to von Frey filaments applied to
the abdominal/perineal area at baseline (before) and
24 hours after bladder HMGB1 instillation of either di-
sulfide HMGB1 or all-thiol HMGB1 (1, 2, 5, 10 and
20 μg). Intravesical vehicle control, 1 or 2 μg of disulfide
HMGB1 did not cause any abdominal mechanical hyper-
sensitivity 24 hours after instillation (Fig. 1a-c). Figure 1d
shows that 5 μg (n = 5) of disulfide HMGB1 resulted in
significant mechanical hypersensitivity of abdominal/
perineal area only with the highest filament tested
(0.07 g; Fig. 1d). Higher doses of disulfide HMGB1 10
(n = 6) or 20 μg (n = 3) significantly increased von Frey
responses compared to baseline for all filaments tested
(Fig. 1e, f ). In contrast, intravesical all-thiol HMGB1 did
not cause any change in abdominal mechanical hyper-
sensitivity for any of the doses tested (Fig. 1g-k).
Micturition changes after HMGB1 bladder instillation
Table 1 shows micturition volume and frequency
changes after different doses of either disulfide or all-
thiol HMGB1. Only the highest dose of disulfide and all-
thiol HMGB1 (20 μg, n = 3) resulted in a significant de-
crease in volume (141 ± 7 μl, 177 ± 24 μl) compared to
vehicle control treated group (n = 5; 301 ± 39 μl). This
dose of disulfide or all-thiol HMGB1 also increased mic-
turition frequency (7.3 ± 0.7, 4.7 ± 0.3 vs 3.0 ± 0.4 of
PBS). Lower doses of disulfide or all-thiol HMGB1 had
no effect on these two micturition parameters (Table 1).
Histological changes
H&E stained bladder sections from mice that received
different doses of disulfide HMGB1, all-thiol HMGB1 or
vehicle control (PBS) were examined by a pathologist
blinded to the treatment and scored for inflammation
and edema changes (Table 2). Intravesical installation of
vehicle control did not produce any inflammation or
edema (Table 2). Disulfide or all-thiol HMGB1 at doses
< 20 μg did not produce any inflammation while min-
imal inflammation (not statistically significant) was ob-
served after 20 μg of either disulfide or all-thiol
HMGB1. Either disulfide or all-thiol HMGB1 at all doses
tested induced minimal to mild bladder edema and stro-
mal reactive changes in some mice (reactive submucosal
fibrosis with lamina propria expansion, Fig. 2d, Table 2),
not statistically significant compared to vehicle control
(Fig. 2a).
Effect of TLR4 and RAGE antagonism on disulfide HMGB1
induced hypersensitivity
We chose the first dose of disulfide HMGB1 that
showed significantly increased abdominal mechanical
sensitivity across all von Frey filaments (10 μg; Fig. 3a)
without inflammation to test the effect of specific
HMGB1 receptor antagonism. Pretreatment with spe-
cific TLR4 (TAK-242) or RAGE (FPS-ZM1) antago-
nists was used to investigate which receptor signaling
mechanism was activated by intravesical disulfide
HMGB1 resulting in increased abdominal mechanical
hypersensitivity.
Intravesical pretreatment with TAK-242 (TLR4 antag-
onist; 75 μg in 50 μl PBS, n = 4) prior to bladder instilla-
tion completely blocked abdominal mechanical
hypersensitivity induced by disulfide HMGB1 for all the
filaments (Fig. 3b). No difference was detected between
pre and post disulfide HMGB1 instillation (F = 0.028).
On the other hand, disulfide HMGB1-induced abdom-
inal mechanical hypersensitivity was not blocked when
FPS-ZM1 (RAGE antagonist; 250 μg, n = 6) was infused
into the bladder before disulfide HMGB1 bladder instil-
lation (Fig. 3d). There were still significant differences
between pre and post disulfide HMGB1 instillation for
all von Frey filaments (Fig. 3d).
Systemic (intraperitoneally) treatment with either
TLR4 antagonist TAK-242 (3 mg/kg, 30 min pretreat-
ment, n = 5) [11] or RAGE antagonist FPS-ZM1 (10 mg/
kg, 15 min pretreatment, n = 3) [12] before intravesical
infusion of disulfide HMGB1 (10 μg) prevented
HMGB1-induced abdominal mechanical hypersensitivity
(Fig. 3c, e).
Pretreatment of TLR4 and RAGE antagonists on
micturition and histology
Intravesical disulfide HMGB1 (10 μg) did not change
micturition volume or frequency (Table 1). No mictur-
ition changes were observed in groups pre-treated with
TLR4 and RAGE antagonists either intraperitoneally
(TLR4: 274 ± 42 in volume, 4.0 ± 0.7 in frequency;
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Fig. 1 Disulfide and all-thiol HMGB1 dose response effects on abdominal mechanical thresholds. (a) vehicle control, (b) 1 μg (n = 4) and (c) 2 μg (n = 3)
disulfide HMGB1 did not affect abdominal mechanical threshold. (d) 5 μg (n = 5) disulfide HMGB1 significantly increased abdominal sensitivity using a
0.07 g filament. (e) 10 μg (n = 6) and (f) 20 μg (n = 3) disulfide HMGB1 significantly induced abdominal hypersensitivity using all four von Frey
filaments. None of the all-thiol HMGB1 doses (g) 1 μg (n = 3), (h) 2 μg (n = 3), (i) 5 μg (n = 4), (j) 10 μg (n = 5) and (k) 20 μg (n = 3) changed abdominal
mechanical sensitivity. *p < 0.05, **p < 0.01 compared with pre-instillation
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RAGE: 214 ± 37 in volume, 4.0 ± 0.6 in frequency) or
intravesically (TLR4: 231 ± 16.9 in volume, 4.0 ± 0.5 in
frequency; RAGE: 221 ± 19.4 in volume, 4.8 ± 0.3 in fre-
quency) followed by intravesical disulfide HMGB1 when
compared to disulfide HMGB1 instillation only group
(264 ± 25.5 in volume; 4.0 ± 1.0 in frequency).
Pretreatment, either i.p. or intravesically, with TLR4 or
RAGE antagonist did not elicit bladder inflammation
(score = 0). Pretreatment with HMGB1 antagonist (i.p.
or intravesical) followed by intravesical disulfide HMGB1
(10 μg/150) also showed minimal increases (not statisti-
cally significant) in edema (TAK 242, i.p, score = 0.13 ±
0.13; intravesical, score = 0; FPS-ZM1, i.p., score = 0,
intravesical, score = 0.08 ± 0.08) compared to vehicle
control (score = 0) or compared to intravesical disulfide
(10 μg/150 μl alone; 0.5+ 0.22) (Fig. 2b, c, e, f ).
Discussion
We recently reported that intravesical activation of
urothelial PAR4 receptors resulted in release of urothe-
lial HMGB1, which mediated bladder pain [10]. Release
of urothelial adenosine triphosphate (ATP) and activa-
tion of transit receptor potential vanilloid 1 (TRPV1) are
well-described mechanisms of bladder pain [16–19].
Whether HMGB1 elicits bladder pain through ATP and/
or TRPV1 remains to be investigated.
The present study extends our earlier findings since
we clearly demonstrate that HMGB1 infused into the
bladder is capable of inducing abdominal mechanical
hypersensitivity (an indirect index of bladder pain).
Furthermore, the redox state of HMGB1 is important
since only intravesical disulfide HMGB1 but not the
all-thiol (reduced) form induced abdominal mechan-
ical hypersensitivity.
We also examined physiological and histological
changes in response to different doses and different
redox forms of HMGB1 infused intravesically. Changes
in micturition parameters were only observed with the
highest dose of disulfide and all-thiol HMGB1 (20 μg;
decreased micturition volume and increased frequency)
whereas none of the lower doses had any effect on mic-
turition (Table 1). In terms of histological changes, only
the highest dose tested (20 μg) of either disulfide or all-
thiol HMGB1 was able to elicit minimal bladder inflam-
mation (Table 2), while minimal to mild bladder edema
and subtle stromal reactive changes were present with
all doses of either disulfide or all-thiol HMGB1. These
histological findings are consistent with our previous
publication that HMGB1 mediates bladder pain without
overt bladder inflammation [10]. Similarly, intraplantar
injection of HMGB1 at 10 and 20 μg caused paw
withdrawal latency decrease as well as edema but
only 20 μg HMGB1 elicited mild inflammation in
hind paw [20]. Furthermore, our findings that disul-
fide HMGB1 mediates bladder pain in a model with
no overt bladder inflammation extend the findings of
Tanaka et al [5] who found that systemic HMGB1
antagonists could prevent bladder pain after chemical
(cyclophosphamide) injury of the bladder but did not
affect inflammatory changes in this chemical cystitis
model.
Recent studies implicate HMGB1 in mediating pain
both at the organ level and at the central nervous system
level (for a review see Kato J & Svensson CI) [6]. Pain
hypersensitivity was elicited when HMGB1 was injected
into sciatic nerve and anti-HMGB1 treatment alleviated
mechanical allodynia after injury, but the nociceptive
signaling pathway is still unclear [21]. Thrombomodulin
(HMGB1 sequester) treatment alleviates intraplantar in-
jection HMGB1 induced mechanical hypersensitivity,
indicating HMGB1’s peripheral effect in nociception
[20]. As an endogenous inflammatory mediator, HMGB1
influences adjacent neurons and glia, which contributes
to the development of neuropathic pain states [21]. One
report showed an increase in HMGB1 re-distribution
into cytoplasm of sensory neurons in dorsal root gan-
glion in a model of tibial nerve injury induced neuro-
pathic pain [22]. In this model, systemic application of
glycyrrhizin, a HMGB1 blocker, reversed the neuropathic
pain [22]. TLR4 and RAGE receptors were shown to be
Table 1 Effects of intravesical disulfide and all-thiol HMGB1 on
mouse micturition
ds HMGB1 all-thiol HMGB1
Dose (μg) Volume (μl) Freq Volume (μl) Freq
0 301 ± 39.3 3.0 ± 0.4 301 ± 39.3 3.0 ± 0.4
1 288 ± 20.1 3.5 ± 0.6 230 ± 9.2 4.3 ± 0.7
2 359 ± 13.9 2.0 ± 0.0 240 ± 79.8 5.3 ± 1.7
5 255 ± 36.8 3.2 ± 0.9 267 ± 35.0 4.3 ± 0.9
10 264 ± 25.5 4.1 ± 1.0 214 ± 15.8 4.0 ± 0.8
20 141 ± 7.3* 7.3 ± 0.7* 177 ± 23.7* 4.7 ± 0.3*
0 = vehicle control
*p < 0.05 compared with 0 μg disulfide HMGB1
Table 2 Effects of intravesical disulfide and all-thiol HMGB1 on
mouse bladder histology
Inflammation Edema
Dose (μg) ds HMGB1 all-thiol HMGB1 ds HMGB1 all-thiol HMGB1
0 0 0 0 0
1 0 0 0.4 ± 0.2 1.3 ± 0.7
2 0 0 0.7 ± 0.7 0.7 ± 0.3
5 0 0 0 1.0 ± 0.6
10 0 0 0.2 ± 0.2 0.9 ± 0.5
20 0.3 ± 0.3 0.3 ± 0.3 1.0 ± 1.0 0.7 ± 0.7
0 = vehicle control
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mediating nociception differentially in peripheral tissue
and nervous system while HMGB1 redox forms
recognize their receptors respectively [11, 23–27]. TLR4
downregulation in spinal glial cells attenuates mechan-
ical allodynia in a rat model of trinitrobenzene sulfonic
acid induced chronic pancreatitis [28]. On the other
hand, RAGE mRNA and protein were increased in dor-
sal root ganglia after tibial nerve injury and RAGE inhib-
ition by neutralizing antibody reversed the pain related
behavior [29]. There is also evidence that systemic or
intrathecal HMGB1 neutralizing antibody or a specific
antagonist can alleviate pain mediated by TLR4 or
RAGE receptors, suggesting central effect of TLR4 and
RAGE receptors [8, 20].
Two strategies were used in the current study to
identify the HMGB1 receptor mediating the disulfide
HMGB1-induced abdominal mechanical hypersensitiv-
ity. A dose of disulfide HMGB1 (10 μg) that pro-
duced no inflammation and only minimal edema was
chosen for the intravesical infusion. Systemic pretreat-
ment with either a TLR4 (TAK-242) or a RAGE
(FPS-ZM1) antagonist blocked abdominal mechanical
hypersensitivity induced by disulfide HMGB1. Since
both of these antagonists cross the blood-brain bar-
rier [12, 30], the effect may be due to antagonism of
central TLR4 or RAGE receptors and these receptors
mediate pain in other models [24, 25]. We applied
antagonists intravesically to determine whether and
which of these receptors mediated the effect of disul-
fide HMGB1 at the organ level. TLR4 and RAGE re-
ceptors are found in the urothelium [26, 31] and
sacral DRGs [29, 32] also contain TLR4 and RAGE
although whether they innervate the bladder is not
known. Intravesical pretreatment with TLR4 antagon-
ist prevented hypersensitivity caused by disulfide
HMGB1 while RAGE antagonist did not. Taken to-
gether, these findings indicate that TLR4 receptors at
the organ level are responsible for the abdominal
mechanical hypersensitivity induced by bladder infu-
sion of disulfide HMGB1.
Our results also indicate that RAGE receptors
modulate the effects of intravesical infusion of
Fig. 2 Bladder histology after disulfide HMGB1 and pretreatment with intravesical or intraperitoneal HMGB1 receptor antagonists. (a) Intravesical
vehicle control instillation (n = 5), (b) intravesical TAK242 (n = 4), (c) intraperitoneal TLR4 antagonist TAK242 (n = 5), (d) 10 μg disulfide HMGB1
induced submucosal fibrosis with lamina propria expansion (black arrows) (n = 6), (e) intravesical FPS-ZM1 pretreatment (n = 6) or (f) intraperitoneal
RAGE antagonist FPS-ZM1 (n = 3)
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HMGB1 by acting not at the organ (i.e. bladder level)
but possibly at the central nervous system level, since
systemic administration was effective in blocking ab-
dominal mechanical hypersensitivity. This agrees with
the observation by Tanaka, et al. [5] that systemic ad-
ministration of an antibody to HMGB1 or a RAGE
inhibitor blocked cyclophosphamide- induced bladder
pain. In contrast, we show that a systemic TLR4 an-
tagonist administered systemically prevented disulfide
HMGB1-induced bladder pain while Tanaka reported
that a systemic TLR4 inhibitor had no effect on CYP-
induced bladder pain [5]. This discrepancy may be
due to the different method used to elicit bladder
pain. Disulfide HMGB1 resulted in only minimal
histological changes in the bladder while CYP is a
strong chemical irritant that results in severe inflam-
mation and hemorraghic cystitis [4].
PBS/IC is a condition characterized by bladder pain
(or discomfort), frequency and urgency with unclear eti-
ology [33] and in the absence of obvious bladder path-
ology [34]. Our current findings showed that disulfide
HMGB1 elicited pain may account for bladder pain ob-
served in the absence of inflammation. We realize that
our model using intravesical infusion of substances
(PAR4-AP; HMGB1) at doses that cause pain without
accompanying micturition or inflammation changes,
focus only on one aspect of PBS/IC, namely pain, with-
out addressing increased frequency and urgency com-
monly seen in PBS/IC. Still these rodent models are
useful because they are capable of eliciting bladder pain
as a primary effect and not secondary to significant in-
jury and inflammation. As such, they are useful tools in
investigating the physiology of bladder pain in health
and disease.
Fig. 3 TLR4 or RAGE antagonist pretreatment prevented abdominal mechanical hypersensitivity induced disulfide HMGB1. (a) 10 μg disulfide
HMGB1 significantly increased abdominal mechanical sensitivity (percent responses) using all four von Frey filaments (n = 6). (b) Intravesical TLR4
antagonist TAK242 blocked disulfide HMGB1 induced abdominal hypersensitivity (n = 4). (c) Intraperitoneal TAK242 reduced mechanical
hypersensitivity induced by 10 μg disulfide HMGB1 (n = 5). (d) Intravesical infusion of RAGE antagonist PSF-ZM1, however, did not affect
abdominal mechanical hypersensitivity induced by disulfide HMGB1 (n = 6). (e) Intraperitoneal injection of PSF-ZM1 prevented disulfide
HMGB1 induced mechanical hypersensitivity (n = 3). *p < 0.05, **p < 0.01, ***p < 0.001 Twenty-four hours post-instillation compared
with pre-instillation
Ma et al. BMC Physiology  (2017) 17:6 Page 7 of 9
It is possible that urine proteases, already elevated in
PBS/IC patients, activate urothelial PAR4 receptors to
release MIF into the urine [35, 36]. MIF, in turn, acti-
vates urothelial MIF receptors to elicit HMGB1 release.
Oxidation of HMGB1 in the extracellular space [6] or in
the urine results in disulfide HMGB1 that binds to either
urothelial TLR4 receptors to induce further signaling
resulting in bladder pain or may bind directly to the mu-
cosa or possible to elicit bladder pain (Fig. 4). This
schema remains to be validated in the clinical condition
in future studies.
Conclusions
We previously showed that activation of urothelial PAR4
receptors results in release of MIF and HMGB1 increas-
ing abdominal mechanical hypersensitivity without blad-
der inflammation. We now report that HMGB1 infused
directly into the bladder is capable to elicit mechanical
hypersensitivity and this effect is produced by the disul-
fide isoform of HMGB1. Lastly, this effect is mediated
by TLR4 receptors in the bladder and can also be modu-
lated by systemic (presumably central) RAGE receptors.
Neutralizing bladder MIF, MIF receptors, HMGB1 or
antagonism of bladder TLR4 or systemic RAGE recep-
tors may be potential specific and localized targets for
bladder pain relief.
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